About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
RUXOLITINIB (ID 27412) displays a multidimensional biochemical activity profile integrating modulation of enzymatic pathways, receptor‑mediated signalling, mitochondrial bioenergetics, oxidative‑stress homeostasis, ion‑channel dynamics, membrane structural behaviour and transcription‑factor regulation. Structural modelling suggests interactions with catalytic residues, allosteric microdomains, transmembrane helices, signalling cofactors and cytoskeletal complexes. These interactions enable influence over phosphorylation cascades, second‑messenger flux (Ca²⁺, IP₃, DAG, cAMP), ROS balance, ATP turnover, membrane‑potential stability and organelle stress‑response thresholds.
Benefits and Applications
- Receptor–ligand affinity analysis and docking studies
- Enzyme‑kinetic profiling and catalytic‑flux pathway mapping
- Mitochondrial‑function modelling and ATP/ROS system evaluation
- Transcriptomic, metabolomic, proteomic and phosphoproteomic profiling
- Cytoskeletal‑architecture and membrane‑dynamics exploration
- Apoptosis, autophagy, necroptosis and ferroptosis pathway modelling
- SAR/QSAR modelling and compound‑optimisation workflows
- Mechanistic pharmacodynamics and dose–response simulation
Side Effects and Risks
- Oxidative‑stress imbalance and elevated ROS
- Mitochondrial overload or respiratory‑chain suppression
- Disruption of Ca²⁺/Na⁺/K⁺ ion‑homeostasis
- Unintended receptor cross‑talk or inhibitory signal interference
- Cytoskeletal destabilisation and membrane‑integrity reduction
- Dose‑dependent cytotoxicity or programmed‑cell‑death activation
- Transcriptional and epigenetic instability
- Inflammatory‑cascade activation (NF‑κB, MAPK, JNK)
Datasheet
| Molecular Formula | C17H18N6 |
|---|---|
| Molecular Weight | 306.4 g/mol |
| CAS Number | 941678-49-5 |
| Storage Condition | Conditions for safe storage, including any incompatibilities: Keep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition. Recommended storage temperature: Store at -20 °C. |
| Solubility | Soluble in aqueous buffers across a pH of 1-8 |
| Purity | Purity information is available upon request (COA). |
| Synonym | Ruxolitinib; 941678-49-5; INCB018424; INCB-018424; INCB18424 |
| IUPAC/Chemical Name | (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile |
| InChl Key | HFNKQEVNSGCOJV-OAHLLOKOSA-N |
| InChl Code | InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
